Drug Trial Radar · NCT06911112
NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of Osavampator as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
200
Planned (sponsor's estimate)
Start
Mar 31, 2025
Primary completion
Jul 2027
Study completion Jul 2027
Sponsor
- Lead sponsor
- Neurocrine BiosciencesNeurocrine Biosciences (NBIX)
- Sponsor type
- Industry
- First posted
- Apr 4, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study will evaluate the efficacy of osavampator (previously NBI-1065845) compared with placebo as an adjunctive treatment in participants with MDD on improving symptoms of depression.
Conditions
- Major Depressive Disorder
Interventions
OsavampatorDrug
Osavampator tablets
PlaceboDrug
Matching placebo tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline in Total Montgomery-Åsberg Depression Rating Scale (MADRS) Score at Day 56Time frame: Baseline, Day 56
Locations
42 sites in 5 countries. Site status is shown where the registry gives one.
Neurocrine Clinical Site
Huntsville, Alabama · Recruiting
Neurocrine Clinical Site
Bryant, Arkansas · Recruiting
Neurocrine Clinical Site
Cerritos, California · Recruiting
Neurocrine Clinical Site
Glendale, California · Recruiting
Neurocrine Clinical Site
Irvine, California · Withdrawn
Neurocrine Clinical Site
Redlands, California · Recruiting
Neurocrine Clinical Site
San Francisco, California · Recruiting
Neurocrine Clinical Site
Hollywood, Florida · Recruiting
Neurocrine Clinical Site
Miami, Florida · Active not recruiting
Neurocrine Clinical Site
Tampa, Florida · Recruiting
Neurocrine Clinical Site
Atlanta, Georgia · Recruiting
Neurocrine Clinical Site
Louisville, Kentucky · Recruiting
Neurocrine Clinical Site
Boston, Massachusetts · Withdrawn
Neurocrine Clinical Site
Saint Charles, Missouri · Active not recruiting
Neurocrine Clinical Site
New York, New York · Recruiting
Neurocrine Clinical Site
The Bronx, New York · Active not recruiting
Neurocrine Clinical Site
Mason, Ohio · Recruiting
Neurocrine Clinical Site
DeSoto, Texas · Recruiting
Neurocrine Clinical Site
Houston, Texas · Recruiting
Neurocrine Clinical Site
Charlottesville, Virginia · Recruiting
Neurocrine Clinical Site
Kardzhali, Bulgaria · Recruiting
Neurocrine Clinical Site
Plovdiv, Bulgaria · Recruiting
Neurocrine Clinical Site
Rousse, Bulgaria · Recruiting
Neurocrine Clinical Site
Sofia, Bulgaria · Recruiting
Neurocrine Clinical Site
Sofia, Bulgaria · Recruiting
Neurocrine Clinical Site
Varna, Bulgaria · Recruiting
Neurocrine Clinical Site
Kaunas, Lithuania · Recruiting
Neurocrine Clinical Site
Kaunas, Lithuania · Recruiting
Neurocrine Clinical Site
Kaunas, Lithuania · Recruiting
Neurocrine Clinical Site
Klaipėda, Lithuania · Withdrawn
Neurocrine Clinical Site
Vilnius, Lithuania · Recruiting
Neurocrine Clinical Site
Bucharest, Romania · Withdrawn
Neurocrine Clinical Site
Bucharest, Romania · Withdrawn
Neurocrine Clinical Site
Craiova, Romania · Recruiting
Neurocrine Clinical Site
Oradea, Romania · Withdrawn
Neurocrine Clinical Site
Banská Bystrica, Slovakia · Recruiting
Neurocrine Clinical Site
Bojnice, Slovakia · Recruiting
Neurocrine Clinical Site
Bratislava, Slovakia · Recruiting
Neurocrine Clinical Site
Košice, Slovakia · Recruiting
Neurocrine Clinical Site
Rimavská Sobota, Slovakia · Recruiting
Showing 40 of 42 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.